Topical Tacrolimus in Dermatology

1. Drug class and preparation

• Class: Topical calcineurin inhibitor (TCI), macrolide immunomodulator.
• Available as: Ointment 0.03% and 0.1%.
• Brand: Protopic (also generics in many regions).
• Steroid-sparing agent: Particularly useful where topical corticosteroid adverse effects are unacceptable.

2. Mechanism of action

• Fitzpatrick's Dermatology, p. 3554

3. Pharmacological points

• Has good penetration through inflamed skin due to its relatively low molecular weight.
• Systemic absorption is usually minimal with routine topical use and falls as the skin barrier heals.
• Serum drug-level monitoring is not routinely required.
• Absorption can be substantial when there is severe barrier dysfunction, especially in Netherton syndrome, extensive erosions, or large-area/occlusive use.

4. Approved indication

5. Dermatological uses

A. Licensed

• Moderate-to-severe atopic dermatitis

• Face and eyelids
• Neck
• Flexures
• Genital and intertriginous areas
• Areas with steroid atrophy, or where prolonged corticosteroid use is undesirable

B. Common off-label uses

• Vitiligo, especially facial and neck lesions, often combined with narrow-band UVB or excimer light
• Seborrheic dermatitis
• Facial and inverse psoriasis
• Lichen planus, including mucosal disease in selected cases
• Lichen sclerosus, adjunctive or second-line
• Cutaneous lupus erythematosus
• Steroid-sensitive facial dermatoses
• Hailey-Hailey disease
• Pyoderma gangrenosum, localized adjunctive therapy
• Graft-versus-host disease and selected inflammatory genital dermatoses

• Fitzpatrick's Dermatology, p. 3554

6. Dose and method of application

• Apply a thin film twice daily to involved skin.
• Rub in gently.
• Continue emollients regularly, but do not apply them simultaneously. A practical approach is to separate emollient and tacrolimus application by about 2 hours.
• Stop when lesions clear.

• After disease control, apply tacrolimus to previous recurrent sites 2 to 3 times weekly to reduce flares and topical steroid requirement.
• Fitzpatrick's Dermatology, p. 3554

• Occlusion unless specifically advised.
• Large quantities over extensive areas.
• Application to actively infected lesions.
• Eyes and oral ingestion. It may be used on eyelid skin, but should not be instilled into the eye.

7. Advantages over topical corticosteroids

• Does not cause epidermal atrophy.
• Does not cause striae, telangiectasia, or steroid-induced purpura.
• Useful for prolonged intermittent treatment at sensitive sites.
• Reduces need for topical corticosteroids.
• Suitable for proactive maintenance in recurrent AD.

8. Adverse effects

Common

• Transient burning, stinging, warmth, pruritus, or erythema at the application site, especially during the first few days and on excoriated skin.
• This can be reduced by controlling severe inflammation first with a short course of topical corticosteroid, or by refrigeration of the ointment before use.

Less common or important

• Folliculitis, acneiform eruption
• Rosacea or rosacea-like dermatitis, particularly with facial use
• Herpes simplex infection, including concern for eczema herpeticum in atopic patients
• Rare systemic absorption with extensive application or severe barrier impairment
• Fitzpatrick's Dermatology, p. 3555

9. Contraindications and precautions

• Known hypersensitivity to tacrolimus or ointment components
• Netherton syndrome, because of potentially high systemic absorption
• Active bacterial, viral, or fungal infection at the application site
• Premalignant or malignant skin lesions, including suspected cutaneous T-cell lymphoma
• Immunocompromised patients, unless under specialist advice

• Use the minimum amount needed.
• Avoid excessive natural or artificial UV exposure.
• Seek review if lymph nodes enlarge, lesions change atypically, or infection develops.
• Report painful vesicles, crusting, fever, or rapidly worsening eczema, which may indicate eczema herpeticum.

10. Boxed warning and malignancy issue

• Fitzpatrick's Dermatology, pp. 3554-3555
• The US prescribing label retains this warning.

Current status and recent advances, in brief

1. Still an established first-choice steroid-sparing topical agent for sensitive-site AD. It remains especially useful on eyelids, face, flexures, and genital skin, and for proactive intermittent maintenance.
2. Evidence continues to support efficacy in AD. A 2024 Cochrane network meta-analysis of 291 eczema studies found tacrolimus 0.1% among the higher-ranked treatments for short-term patient-reported eczema symptom improvement, although certainty for comparative rankings was low. See the Cochrane review.
3. Vitiligo is an important off-label role. Topical calcineurin inhibitors are supported as first-line topical options in young patients, with treatment courses generally requiring at least 6 months and often used alongside UV-based therapy. Facial lesions respond best. See 2024 vitiligo recommendations.
4. It now has more competitors. Newer topical therapies such as PDE-4 inhibitors, aryl-hydrocarbon receptor agonists, and topical JAK inhibitors have broadened options for AD; topical ruxolitinib has also changed the treatment landscape for nonsegmental vitiligo. Tacrolimus remains valuable because it is familiar, non-atrophogenic, usable at delicate sites, and usually less costly than newer agents.
5. Safety position: Current practice recognizes very low systemic exposure in ordinary use, but still respects label precautions, particularly avoiding use on infected or suspicious lesions, avoiding extensive/occlusive application, and taking special care in severe barrier-defect disorders.

One-line viva answer